Shots:

• The P-III trial evaluates Dupixent + SoC low-potency TCS vs TCS alone (PBO) in 162 children aged 6mos. to 5yrs. with AD. The therapy is being developed in collaboration with Regeneron
• The trial met all 1EPs & 2EPs i.e., @16wks, patients achieved clear or almost clear skin (28% vs 4%), ≥75% improvement in overall disease severity (53% vs 11%), an improvement in itch & EASI (49% vs 2%) & (70% vs 20%) & the safety profile was consistent with the safety profile of Dupixent
• The company is planning for regulatory submission in the US at the end of 2021 & EU in H1’22. The therapy is approved in the US, EU, Japan & other countries globally for AD & asthma or CRSwNP in different age populations

Ref: Globe Newswire | Image: Sanofi